Mesoblast Ltd (MESO) SEC Filing 6-K Foreign Issuer Report for the period ending Friday, October 21, 2022

Mesoblast Ltd

CIK: 1345099 Ticker: MESO

View differences made from one to another to evaluate Mesoblast Ltd's financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 6-K Foreign Issuer Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Mesoblast Ltd.


Assess how Mesoblast Ltd's management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Mesoblast Ltd's Definitive Proxy Statement (Form DEF 14A) filed after their 2022 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors


SEC Filing Tools

Material Contracts, Statements, Certifications & more

Mesoblast Ltd provided additional information to their SEC Filing as exhibits

Ticker: MESO
CIK: 1345099
Form Type: 6-K Foreign Issuer Report
Accession Number: 0001564590-22-034915
Submitted to the SEC: Fri Oct 21 2022 8:01:45 PM EST
Accepted by the SEC: Mon Oct 24 2022
Period: Friday, October 21, 2022
Industry: Biological Products No Disgnostic Substances

External Resources:
Stock Quote
Social Media

Bookmark the Permalink: